MICROBOT Aktie

 

Microbot Medical® Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY® Endovascular Robotic System...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S....

First U.S. Based Medical Meeting Presence Post-FDA Clearance Will Allow the Company to Commercially Engage Future Potential Users of the LIBERTY® System...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

The Experienced MedTech Logistics Provider Will Help Ensure Effective and Efficient Inventory Management and Customer Support The Company is on Track to Commence the Launch of LIBERTY® during Q4 This Year...

$25.2 million in first closing, $1.2 million in second closing and $2.8 million in third and final closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment options $25.2 million in first closing, $1.2 million in second closing and $2.8 million in third and final closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment options...

Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices ...

Microbot Medical (MBOT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....

$25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment options $25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment options...

$25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment options $25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment options...

MBOT shares rise as FDA clears its LIBERTY robotic system, paving the way for U.S. market entry and fueling strong investor momentum....

Live Presentation to be Webcast Today at 9am ET Live Presentation to be Webcast Today at 9am ET...

The US Food and Drug Administration has granted clearance to Microbot Medical's Liberty endovascular robotic system....

Microbot Medical® Receives FDA 510(k) Clearance for Its LIBERTY® Endovascular Robotic System....

MBOT's new U.S. patent boosts the LIBERTY system's flexibility, expanding its U.S. market reach to over six million annual procedures....

With the Newly Granted IP, the Company's IP Portfolio for the LIBERTY® System now includes 12 patents granted globally and 57 patent applications pending....

Strengthens Balance Sheet and Continues Commercialization Readiness Plans for the LIBERTY® System as it Nears FDA Marketing Clearance Decision Strengthens Balance Sheet and Continues Commercialization Readiness Plans for the LIBERTY® System as it Nears FDA Marketing Clearance Decision...

Microbot Medical has appointed seasoned medical device executive and two-time Olympian Christina Bailey as Vice President of Sales....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...